Principal Financial Group Inc. Raises Holdings in Edwards Lifesciences Corporation $EW

Principal Financial Group Inc. increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 821,825 shares of the medical research company’s stock after acquiring an additional 16,583 shares during the period. Principal Financial Group Inc.’s holdings in Edwards Lifesciences were worth $70,061,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC increased its holdings in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares in the last quarter. Sei Investments Co. increased its holdings in Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after acquiring an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its stake in shares of Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after acquiring an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $82.75 on Friday. The stock has a market capitalization of $47.71 billion, a P/E ratio of 44.01, a PEG ratio of 2.09 and a beta of 0.87. The business has a 50 day simple moving average of $82.16 and a two-hundred day simple moving average of $82.74. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Wednesday, April 1st. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Finally, TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.65.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the completion of the sale, the vice president directly owned 33,682 shares in the company, valued at $2,828,614.36. This represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,704,682.56. This represents a 51.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 88,096 shares of company stock valued at $7,288,799 over the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.